Seek Returns

AMGN vs. HALO: Amgen vs. Halozyme Therapeutics Stock Comparison

How do Amgen (AMGN) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Halozyme Therapeutics (HALO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Amgen (AMGN) and Halozyme Therapeutics (HALO)
Profile ItemAMGNHALO
NameAmgen Inc. Common StockHalozyme Therapeutics Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization249.05 billion USD11.81 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 17, 1983March 16, 2004
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AMGN
HALO
GSPC
Loading price history…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Halozyme Therapeutics (HALO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Halozyme Therapeutics (HALO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
Total Return (1Y)48.82%50.94%
Total Return (3Y, Annualized)24.31%41.08%
Total Return (5Y, Annualized)20.67%21.68%

Risk Profile

Drawdown History

AMGN
HALO
GSPC
Loading price history…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Halozyme Therapeutics (HALO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
Volatility (1Y, Annualized)29.12%41.19%
Beta (5Y)0.430.96
Max Drawdown (5Y)-24.86%-49.06%
Avg. Volume (3M)2.76M2.29M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and HALO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
Sharpe Ratio (1Y)1.531.13
Sortino Ratio (1Y)2.361.78

Profitability

ROE (TTM)

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Amgen (AMGN) at 78.35% also sits in the top quartile.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max
109.18%
AMGN
78.35%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO
216.38%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Amgen (AMGN) at 24.14% and Halozyme Therapeutics (HALO) at 26.93% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN
24.14%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO
26.93%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max
83.12%
AMGN
35.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Max
83.12%
HALO
59.84%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
ROE (TTM)78.35%216.38%
ROA (TTM)8.91%22.42%
Net Margin (TTM)24.14%26.93%
Operating Margin (TTM)35.79%59.84%
Gross Margin (TTM)72.47%77.74%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Halozyme Therapeutics (HALO) at -25.36% is closer to the peer norm — faster per-share earnings growth for AMGN.

Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
Revenue Growth (YoY)9.95%37.55%
Revenue Growth (3Y CAGR)11.77%28.38%
EPS Growth (YoY)88.23%-25.36%
EPS Growth (3Y CAGR)5.52%21.14%

Financial Strength

Current Ratio (MRQ)

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AMGN
1.48
Min
0.10

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max
25.13
Q3
12.13
Median
5.52
HALO
3.88
Q1
2.47
Min
0.10
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Amgen (AMGN) carries debt-to-equity ratio of 3.76 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN
3.76
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
HALO
--
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): HALO does not report debt-to-equity ratio, so it has no value marker; AMGN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
Current Ratio (MRQ)1.483.88
Debt / Equity (MRQ)3.76--
Net Debt / EBITDA2.311.90

Dividends

Dividend Yield (TTM)

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN
2.16%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN
57.62%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
Dividend Yield (TTM)2.16%0.00%
Dividend Payout Ratio (TTM)57.62%0.00%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 26.69 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max
85.34
Q3
43.46
AMGN
26.69
Median
26.69
Q1
13.30
Min
0.07

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Max
85.34
Q3
43.46
Median
26.69
HALO
25.91
Q1
13.30
Min
0.07
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max
58.18
Q3
25.77
Median
7.30
AMGN
6.40
Q1
3.01
Min
0.01

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max
58.18
Q3
25.77
Median
7.30
HALO
6.55
Q1
3.01
Min
0.01
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Amgen (AMGN) reports 17.35, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN
17.35
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
HALO
-213.67
Loading chart…
Amgen (AMGN) vs. Halozyme Therapeutics (HALO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Halozyme Therapeutics (HALO)
MetricAMGNHALO
P/E Ratio (TTM)26.6925.91
P/S Ratio (TTM)6.406.55
P/B Ratio (MRQ)17.35-213.67
Free Cash Flow Yield (TTM)2.96%3.48%